Cargando…

Cardiovascular magnetic resonance T2* mapping for the assessment of cardiovascular events in hypertrophic cardiomyopathy

BACKGROUND: Hypertrophic cardiomyopathy (HCM) is associated with an increased risk of adverse cardiac events. Beyond classic risk factors, relative myocardial ischaemia and succeeding myocardial alterations, which can be detected using either contrast agents or parametric mapping in cardiovascular m...

Descripción completa

Detalles Bibliográficos
Autores principales: Gastl, Mareike, Gruner, Christiane, Labucay, Karin, Gotschy, Alexander, Von Spiczak, Jochen, Polacin, Malgorzata, Boenner, Florian, Kelm, Malte, Ruschitzka, Frank, Alkadhi, Hatem, Kozerke, Sebastian, Manka, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076262/
https://www.ncbi.nlm.nih.gov/pubmed/32201584
http://dx.doi.org/10.1136/openhrt-2019-001152
_version_ 1783507185728225280
author Gastl, Mareike
Gruner, Christiane
Labucay, Karin
Gotschy, Alexander
Von Spiczak, Jochen
Polacin, Malgorzata
Boenner, Florian
Kelm, Malte
Ruschitzka, Frank
Alkadhi, Hatem
Kozerke, Sebastian
Manka, Robert
author_facet Gastl, Mareike
Gruner, Christiane
Labucay, Karin
Gotschy, Alexander
Von Spiczak, Jochen
Polacin, Malgorzata
Boenner, Florian
Kelm, Malte
Ruschitzka, Frank
Alkadhi, Hatem
Kozerke, Sebastian
Manka, Robert
author_sort Gastl, Mareike
collection PubMed
description BACKGROUND: Hypertrophic cardiomyopathy (HCM) is associated with an increased risk of adverse cardiac events. Beyond classic risk factors, relative myocardial ischaemia and succeeding myocardial alterations, which can be detected using either contrast agents or parametric mapping in cardiovascular magnetic resonance (CMR) imaging, have shown an impact on outcome in HCM. CMR may help to risk stratify using parametric T2* mapping. Therefore, the aim of the present study was to evaluate the association of T2* values or fibrosis with cardiovascular events in HCM. METHODS: The relationship between T2* with supraventricular, ventricular arrhythmia or heart failure was retrospectively assessed in 91 patients with HCM referred for CMR on a 1.5T MR imaging system. Fibrosis as a reference was added to the model. Patients were subdivided into groups according to T2* value quartiles. RESULTS: 47 patients experienced an event of ventricular arrhythmia, 25 of atrial fibrillation/flutter and 17 of heart failure. T2*≤28.7 ms yielded no association with ventricular events in the whole HCM cohort. T2* of non-obstructive HCM showed a significant association with ventricular events in univariate analysis, but not in multivariate analysis. For the combined endpoint of arrhythmic events, there was already an association for the whole HCM cohort, but again only in univariate analyses. Fibrosis stayed the strongest predictor in all analyses. There was no association for T2* and fibrosis with heart failure. CONCLUSIONS: Decreased T2* values by CMR only provide a small association with arrhythmic events in HCM, especially in non-obstructive HCM. No information is added for heart failure.
format Online
Article
Text
id pubmed-7076262
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-70762622020-03-20 Cardiovascular magnetic resonance T2* mapping for the assessment of cardiovascular events in hypertrophic cardiomyopathy Gastl, Mareike Gruner, Christiane Labucay, Karin Gotschy, Alexander Von Spiczak, Jochen Polacin, Malgorzata Boenner, Florian Kelm, Malte Ruschitzka, Frank Alkadhi, Hatem Kozerke, Sebastian Manka, Robert Open Heart Heart Failure and Cardiomyopathies BACKGROUND: Hypertrophic cardiomyopathy (HCM) is associated with an increased risk of adverse cardiac events. Beyond classic risk factors, relative myocardial ischaemia and succeeding myocardial alterations, which can be detected using either contrast agents or parametric mapping in cardiovascular magnetic resonance (CMR) imaging, have shown an impact on outcome in HCM. CMR may help to risk stratify using parametric T2* mapping. Therefore, the aim of the present study was to evaluate the association of T2* values or fibrosis with cardiovascular events in HCM. METHODS: The relationship between T2* with supraventricular, ventricular arrhythmia or heart failure was retrospectively assessed in 91 patients with HCM referred for CMR on a 1.5T MR imaging system. Fibrosis as a reference was added to the model. Patients were subdivided into groups according to T2* value quartiles. RESULTS: 47 patients experienced an event of ventricular arrhythmia, 25 of atrial fibrillation/flutter and 17 of heart failure. T2*≤28.7 ms yielded no association with ventricular events in the whole HCM cohort. T2* of non-obstructive HCM showed a significant association with ventricular events in univariate analysis, but not in multivariate analysis. For the combined endpoint of arrhythmic events, there was already an association for the whole HCM cohort, but again only in univariate analyses. Fibrosis stayed the strongest predictor in all analyses. There was no association for T2* and fibrosis with heart failure. CONCLUSIONS: Decreased T2* values by CMR only provide a small association with arrhythmic events in HCM, especially in non-obstructive HCM. No information is added for heart failure. BMJ Publishing Group 2020-03-15 /pmc/articles/PMC7076262/ /pubmed/32201584 http://dx.doi.org/10.1136/openhrt-2019-001152 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Heart Failure and Cardiomyopathies
Gastl, Mareike
Gruner, Christiane
Labucay, Karin
Gotschy, Alexander
Von Spiczak, Jochen
Polacin, Malgorzata
Boenner, Florian
Kelm, Malte
Ruschitzka, Frank
Alkadhi, Hatem
Kozerke, Sebastian
Manka, Robert
Cardiovascular magnetic resonance T2* mapping for the assessment of cardiovascular events in hypertrophic cardiomyopathy
title Cardiovascular magnetic resonance T2* mapping for the assessment of cardiovascular events in hypertrophic cardiomyopathy
title_full Cardiovascular magnetic resonance T2* mapping for the assessment of cardiovascular events in hypertrophic cardiomyopathy
title_fullStr Cardiovascular magnetic resonance T2* mapping for the assessment of cardiovascular events in hypertrophic cardiomyopathy
title_full_unstemmed Cardiovascular magnetic resonance T2* mapping for the assessment of cardiovascular events in hypertrophic cardiomyopathy
title_short Cardiovascular magnetic resonance T2* mapping for the assessment of cardiovascular events in hypertrophic cardiomyopathy
title_sort cardiovascular magnetic resonance t2* mapping for the assessment of cardiovascular events in hypertrophic cardiomyopathy
topic Heart Failure and Cardiomyopathies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076262/
https://www.ncbi.nlm.nih.gov/pubmed/32201584
http://dx.doi.org/10.1136/openhrt-2019-001152
work_keys_str_mv AT gastlmareike cardiovascularmagneticresonancet2mappingfortheassessmentofcardiovasculareventsinhypertrophiccardiomyopathy
AT grunerchristiane cardiovascularmagneticresonancet2mappingfortheassessmentofcardiovasculareventsinhypertrophiccardiomyopathy
AT labucaykarin cardiovascularmagneticresonancet2mappingfortheassessmentofcardiovasculareventsinhypertrophiccardiomyopathy
AT gotschyalexander cardiovascularmagneticresonancet2mappingfortheassessmentofcardiovasculareventsinhypertrophiccardiomyopathy
AT vonspiczakjochen cardiovascularmagneticresonancet2mappingfortheassessmentofcardiovasculareventsinhypertrophiccardiomyopathy
AT polacinmalgorzata cardiovascularmagneticresonancet2mappingfortheassessmentofcardiovasculareventsinhypertrophiccardiomyopathy
AT boennerflorian cardiovascularmagneticresonancet2mappingfortheassessmentofcardiovasculareventsinhypertrophiccardiomyopathy
AT kelmmalte cardiovascularmagneticresonancet2mappingfortheassessmentofcardiovasculareventsinhypertrophiccardiomyopathy
AT ruschitzkafrank cardiovascularmagneticresonancet2mappingfortheassessmentofcardiovasculareventsinhypertrophiccardiomyopathy
AT alkadhihatem cardiovascularmagneticresonancet2mappingfortheassessmentofcardiovasculareventsinhypertrophiccardiomyopathy
AT kozerkesebastian cardiovascularmagneticresonancet2mappingfortheassessmentofcardiovasculareventsinhypertrophiccardiomyopathy
AT mankarobert cardiovascularmagneticresonancet2mappingfortheassessmentofcardiovasculareventsinhypertrophiccardiomyopathy